Stock MRSN MERSANA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.31 USD +5.48% Intraday chart for Mersana Therapeutics, Inc. -1.70% -0.43%
May. 09 Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mersana Therapeutics to Present at Upcoming Investor Conferences
AQ
Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M
MT
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
AQ
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
AQ
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
North American Morning Briefing : Markets on Hold -2-
DJ
JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5
MT
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) added to S&P Biotechnology Select Industry Index
CI
Truist Securities Upgrades Mersana Therapeutics to Buy From Hold, Price Target is $9
MT
Guggenheim Upgrades Mersana Therapeutics to Buy From Neutral, Price Target is $7
MT
Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2
MT
Transcript : Mersana Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q4 Revenue $10.7M, vs. Street Est of $14.8M
MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Mersana Therapeutics to Present at Upcoming Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRSN Stock
  4. News Mersana Therapeutics, Inc.